Search Results 341-350 of 16699 for alopecia

1. A Study of SC-006 in Subjects With Advanced Cancer - Mayo Clinic

   Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia and peripheral neuropathy) prior to initiation of study drug administration.

2. A Study of PY314 in Subjects With Advanced Solid Tumors - Mayo Clinic

   alopecia or peripheral neuropathy, or if controlled on thyroid replacement therapy). - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ...

3. A Study of IPI-926 for Patients with Myelofibrosis - Mayo Clinic

   ... alopecia; Females. Be of non-child bearing potential; If of child-bearing potential defined as a sexually mature woman who. Has not undergone surgical ...

4. A Study to Evaluate Genetic Testing in Guiding Treatment for Patients with Brain Metastases - Mayo Clinic

   ... alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and ...

5. Olaparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer - Mayo Clinic

   ... alopecia). Patients must not have had nitrosoureas or mitomycin C for 6 weeks prior to the initiation of study treatment. Radiation: Prior radiation therapy ...

6. Radiation Therapy in Treating Patients with Extensive Stage Small Cell Lung Cancer - Mayo Clinic

   Recovered from prior chemotherapy (i.e., toxicities ≤ grade 1 [except for neuropathy and alopecia]); Thoracic radiotherapy administered concurrently with or ...

7. Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma - Mayo Clinic

   ... alopecia and fatigue. Total bilirubin =< 1.5 x the upper limits of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ...

8. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

9. A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma - Mayo Clinic

   ... alopecia and decreased tendon reflex and to ≤ Grade 1 for all other effects at the time of enrollment, unless otherwise noted. Consult with the Lilly ...

10. A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial - Mayo Clinic

    Patient must have recovered from any adverse events due to prior anti-cancer therapy (i.e., have no residual toxicities > grade 1 with the exception of alopecia ...